Koers Teva Pharmaceutical Industries Limited Other OTC
Aandelen
TEVJF
IL0006290147
Farmaceutische producten
Omzet 2024 * | 15,95 mld. 14,66 mld. | Omzet 2025 * | 16,52 mld. 15,18 mld. | Marktkapitalisatie | 19,36 mld. 17,79 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 820 mln. 754 mln. | Nettowinst (verlies) 2025 * | 1,39 mld. 1,27 mld. | EV/omzet 2024 * | 2,15 x |
Nettoschuld 2024 * | 14,93 mld. 13,72 mld. | Nettoschuld 2025 * | 12,41 mld. 11,41 mld. | EV/omzet 2025 * | 1,92 x |
K/w-verhouding 2024 * |
18,2
x | K/w-verhouding 2025 * |
12,7
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 89,71% |
Recentste transcriptie over Teva Pharmaceutical Industries Limited
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Richard Francis
CEO | Chief Executive Officer | 55 | 01-01-23 |
Eli Kalif
DFI | Director of Finance/CFO | 51 | 22-12-19 |
Eric Hughes
CTO | Chief Tech/Sci/R&D Officer | - | 01-08-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Gerald Lieberman
BRD | Director/Board Member | 77 | 01-09-15 |
Janet Vergis
BRD | Director/Board Member | 59 | 09-06-20 |
Sol Barer
CHM | Chairman | 76 | 01-01-15 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+31,37% | 588 mld. | |
-2,81% | 364 mld. | |
+20,43% | 326 mld. | |
+5,38% | 285 mld. | |
+14,83% | 239 mld. | |
+9,93% | 210 mld. | |
-6,95% | 200 mld. | |
+10,90% | 167 mld. | |
+0,14% | 161 mld. |